Please check your internet connection and try again.
# Methycobalime (Methylcobalamin)
## Overview
Methylcobalamin is a biologically active form of Vitamin B12 (cobalamin). Unlike cyanocobalamin, it does not require conversion by the liver to become metabolically active and functions as an essential cofactor for methionine synthase, which catalyzes the conversion of homocysteine to methionine.
## Primary Indications
* Peripheral neuropathy (diabetic or alcoholic origin).
* Megaloblastic anemia due to Vitamin B12 deficiency.
* Adjunctive therapy for diabetic retinopathy or neurological disorders.
## Adult Dosing
* **Peripheral Neuropathy:** 1500 mcg daily, administered in three divided doses (500 mcg three times daily).
* **Maintenance/Nutritional Support:** Dosing varies widely by regional product labeling; common oral regimens range from 500 mcg to 1500 mcg daily.
* **Parenteral (IM/IV):** 500 mcg, 1–3 times weekly, depending on severity and clinical response.
## Pediatric Dosing
* **Established Dosing:** No standardized pediatric dosing exists for methylcobalamin; usage is generally off-label and based on clinical judgment. Consult institutional pediatric protocols or endocrine guidelines for B12 deficiency management.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No formal dose adjustments established. Toxicity is rare due to water-soluble nature and high threshold for renal clearance.
## Contraindications
* Hypersensitivity to cobalt, cobalamin, or any component of the formulation.
* Early Leber’s optic atrophy (may lead to rapid progression).
## Adverse Effects
* **Common:** Gastrointestinal upset (anorexia, nausea, diarrhea), headache, and mild skin rashes.
* **Rare:** Anaphylaxis (very rare, generally associated with parenteral administration).
## Key Drug Interactions
* **Chloramphenicol:** May attenuate the hematological response to Vitamin B12.
* **Colchicine/Heavy alcohol intake:** May decrease Vitamin B12 absorption.
* **Proton Pump Inhibitors (PPIs) and H2-blockers:** Long-term use may reduce the absorption of oral cobalamins.
## Monitoring
* **Baseline:** Complete blood count (CBC) and serum B12 levels.
* **Follow-up:** Monitor symptoms of neurological recovery (e.g., paresthesia reduction) and hematological markers (hemoglobin/hematocrit, MCV) if treating anemia.
* **Electrolytes:** Periodic monitoring of potassium levels is recommended during initial treatment of severe megaloblastic anemia, as sudden stimulation of erythropoiesis can induce hypokalemia.
## Clinical Pearls
* **Bioavailability:** Superior to cyanocobalamin in patients with impaired hepatic function or specific genetic polymorphisms (MTHFR).
* **Efficacy:** Effectiveness is significantly higher in patients with documented B12 deficiency rather than idiopathic neuropathy.
* **Administration:** Oral forms are generally well-absorbed, but sublingual administration may be prioritized in patients with malabsorption syndromes (e.g., pernicious anemia or post-gastrectomy).
* **Dosing Variation:** Always check specific manufacturer guidelines as regional products (e.g., Japanese formulas) vary significantly in concentration compared to compounding pharmacy preparations.
***
**Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Please verify all dosages and contraindications against current local prescribing information, clinical guidelines, and the manufacturer’s product insert before administration.
